These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21684857)

  • 41. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
    Luetkemeyer AF; Rosenkranz SL; Lu D; Marzan F; Ive P; Hogg E; Swindells S; Benson CA; Grinsztejn B; Sanne IM; Havlir DV; Aweeka F;
    Clin Infect Dis; 2013 Aug; 57(4):586-93. PubMed ID: 23592830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
    Landolt NK; Phanuphak N; Ubolyam S; Pinyakorn S; Kriengsinyot R; Ahluwalia J; Thongpaeng P; Gorowara M; Thammajaruk N; Chaithongwongwatthana S; Lange JM; Ananworanich J
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):534-9. PubMed ID: 23187949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
    Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Renaud-Théry F; Shaffer N; Hargreaves S; Mills EJ; Ford N
    AIDS; 2013 Jun; 27(9):1403-12. PubMed ID: 23343913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sequencing to NRTI plus NNRTI-only combinations after virological failure of protease inhibitor-based combination HIV-1 therapy.
    Asboe D; Mandalia S; Gazzard BG
    HIV Clin Trials; 2003; 4(1):1-10. PubMed ID: 12577191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone.
    Chimsuntorn S; Sungkanuparph S; Manosuthi W
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(1):43-5. PubMed ID: 20071597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
    Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
    Ngayo MO; Oluka M; Bulimo WD; Okalebo FA
    Sci Rep; 2021 Nov; 11(1):22071. PubMed ID: 34764325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Ouattara E; Moh R; Amani-Bosse C; Messou E; Sissoko M; Anglaret X; Eholié SP; Danel C; Dabis F; ;
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):183-7. PubMed ID: 21084995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
    Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
    Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
    J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
    Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
    Matteelli A; Regazzi M; Villani P; De Iaco G; Cusato M; Carvalho AC; Caligaris S; Tomasoni L; Manfrin M; Capone S; Carosi G
    Curr HIV Res; 2007 May; 5(3):349-53. PubMed ID: 17504177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.